June 27, 2019
The 93rd edition of the HPRA Drug Safety Newsletter.
The 93rd edition of the HPRA Drug Safety Newsletter includes information on the following medicines:
Domperidone-containing medicines: No longer approved for use in children due to lack of efficacy
Direct oral anticoagulants (DOACs) are not recommended in patients with antiphopholipid syndrome (APS) due to possible increased risk of recurrent thrombotic events
Use of Xeljanz (tofacitinib) restricted in patients at high risk of pulmonary embolism whicle EMA review is ongoing.
The online versions of the DSN contains hyperlinks to product information and other documents on the HPRA and European Medicines Agency (EMA) websites, as appropriate.